Literature DB >> 20534398

Update on the surgical pathology standards on rectal cancer diagnosis, staging and quality assessment of surgery.

Alejandro Rojo1, Pilar Sancho, Oscar Alonso, Sara Encinas, Gemma Toledo, Juan F García.   

Abstract

Surgery for rectal cancer continues to develop towards improving local control and overall survival, maintaining quality of life and preserving sphincter, genitourinary and sexual function. The multidisciplinary approach integrated in a team of different specialists ensures an individualised treatment for each patient with rectal cancer. Thus, the role of the pathologist has acquired an important relevance, not only in diagnosis, management and evaluation of the surgical specimen, but also for selection of the best adjuvant treatment. Parameters such as macroscopic quality of the mesorectum, status of the circumferential margin and lymph node harvest are considered basic criteria by current guidelines. Additionally, consistency in reporting based on the histologic classification proposed by the World Health Organization (WHO) is mandatory, along with inclusion into the pathologic report of current criteria for tumour node metastasis (TNM) staging, assessment of response to neoadjuvant chemoradiation therapy and clinically relevant molecular studies. Detection of defects in mismatch repair genes and mutational analysis of specific genes should be included as predictive markers for therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20534398     DOI: 10.1007/s12094-010-0530-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  22 in total

Review 1.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

Review 2.  Clarifying margins in the multidisciplinary management of rectal cancer: the MERCURY experience.

Authors:  G Salerno; I R Daniels; B J Moran; A Wotherspoon; G Brown
Journal:  Clin Radiol       Date:  2006-11       Impact factor: 2.350

3.  A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum.

Authors:  Hakjung Kang; Jessica B O'Connell; Melinda A Maggard; Jonathan Sack; Clifford Y Ko
Journal:  Dis Colon Rectum       Date:  2005-06       Impact factor: 4.585

4.  Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability.

Authors:  Joel K Greenson; Joseph D Bonner; Ofer Ben-Yzhak; Hector I Cohen; Ines Miselevich; Murray B Resnick; Philippe Trougouboff; Lynn D Tomsho; Evelyn Kim; Marcelo Low; Ronit Almog; Gad Rennert; Stephen B Gruber
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

5.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

6.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

7.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

8.  A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.

Authors:  Xavier Bessa; Belen Ballesté; Montserrat Andreu; Antoni Castells; Beatriz Bellosillo; Francesc Balaguer; Sergi Castellví-Bel; Artemio Paya; Rodrigo Jover; Cristina Alenda; Llúcia Titó; Mercedes Martinez-Villacampa; Angels Vilella; Rosa M Xicola; Elisenda Pons; Xavier Llor
Journal:  Clin Gastroenterol Hepatol       Date:  2007-12-21       Impact factor: 11.382

Review 9.  Training and quality assurance for rectal cancer: 20 years of data is enough.

Authors:  Phil Quirke
Journal:  Lancet Oncol       Date:  2003-11       Impact factor: 41.316

10.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

View more
  3 in total

Review 1.  [R1 resection in rectal cancer].

Authors:  H-R Raab
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

Review 2.  Multidisciplinary management in rectal cancer.

Authors:  Asunción Hervás Morón; María Luisa García de Paredes; Eduardo Lobo Martínez
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

3.  The impact of standard protocol implementation on the quality of colorectal cancer pathology reporting.

Authors:  Peter Ihnát; Patricie Delongová; Jaroslav Horáček; Lucia Ihnát Rudinská; Petr Vávra; Pavel Zonča
Journal:  World J Surg       Date:  2015-01       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.